OptimizeRx Corp

OPRX
About the company

OptimizeRx Corporation operates as a digital healthcare technology company.

Country: United StatesPrice: $7.34Market Cap: $138.3M

Investment snapshot

41%positive consensus
Scored 1d ago

Positive

6

BUY / PASS

Neutral / negative

2 / 8

NEUTRAL / FAIL

Median fair value

$7.47

+1.8% vs price

Models with upside

3 / 17

Positive margin of safety

Strongest signal

9 of 12 pass — Buffett, Marks and Asness object

Key risk

14 of 16 flag OPRX's profitability — Graham, Buffett, Lynch +11 more

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILBUYBUY · Rank #320 (Top 10.3%)BUYPASSPASSNEUTRALFAILFAILPASSPASSFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-13.8%-24.0%-8.7%N/AN/AN/A+69.1%+10.5%N/AN/A+79.4%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

TTM ended 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-12

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-12

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage75% pass✓ 12✗ 3▾

    9 of 12 pass — Buffett, Marks and Asness object

    LT Debt vs Net Current AssetsLT Debt $17.8M vs NCA $44.4M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.15, IC: 2.3x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.15
    ✓Lynch< 0.33
    Cash - Long-term Debt$6.3M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change18.00% -> 12.11%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities5.58
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.15
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.15
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=2.3x, D/EBITDA=1.2x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.15
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.1450; #1484/4210 (top 35.2%)
    ✗AsnessTop 30% of eligible cross-section
  • Cash Flow70% pass✓ 9✗ 3▾

    7 of 10 pass — Marks, Sleep and Oshaughnessy object

    Free Cash Flow Proxy$9.4M
    ✓BuffettPositive and growing
    FCF Positive and Growing$18.7M
    ✓LynchPositive and growing
    Operating Cash Flow$18.7M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=10.58%, ROA=2.90%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)7.4x
    ✓Dreman< 8x
    P/E or FCF YieldP/E=27.2x, FCF Yield=13.5%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive7/18 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap13.3%
    ✓Ackman>= 4%
    Price / FCF per Share7.4x
    ✓Ackman<= 25
    Positive Operating Cash Flow frequency7/18 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$18.4M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+13.28%; #484/4519 (top 10.7%)
    ✗OshaughnessyTop 10% of eligible cross-section

Where It Falls Short

  • Profitability13% pass✓ 11✗ 24▾

    14 of 16 flag OPRX's profitability — Graham, Buffett, Lynch +11 more

    Positive EPS (10 years)3/18 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)3/18 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-7.2%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)10.7% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$9.4M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)0.30
    ✓Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR91.7%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    ROE3.5%
    ✗Lynch> 15%
    EBIT / Enterprise Value8.2%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=8.2%, ROC=50.3%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets2.90%
    ✓PiotroskiROA > 0
    ROA Change YoY-11.75% -> 2.90% (delta: +14.65%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=10.58%, ROA=2.90%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY64.5% -> 67.3%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue6.9%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity3.5%
    ✗Dreman> 12%
    Margin of SafetyP/E=27.2x, P/B=1.1x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-9.0% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency3/16 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue11.1%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity3.5%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-36.9% (2023) -> 10.7% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 60.0% -> 67.3%, operating margin -36.9% -> 10.7%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+3.33%; #2266/6340 (top 35.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+41.60%; #906/3702 (top 24.5%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity+3.51%; #2617/5226 (top 50.1%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0580; #2762/5884 (top 46.9%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR91.7% over 4 years
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years3/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Growth25% pass✓ 7✗ 6▾

    6 of 8 flag OPRX's growth — Graham, Marks, Ackman +3 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)0.30
    ✓Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR91.7%
    ✓Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-0.02 (2013) -> $0.27 (2025)
    ✓DremanPositive over recent years
    EPS CAGR45.0% CAGR over 7 years
    ✓Dreman> 5% annualized
    Positive Net Income Frequency3/16 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth18.8%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 60.0% -> 67.3%, operating margin -36.9% -> 10.7%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR20.4%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR91.7% over 4 years
    ✗Neff7%-20% annualized
  • Valuation31% pass✓ 11✗ 17▾

    9 of 13 flag OPRX's valuation — Graham, Greenblatt, Dreman +6 more

    Price / Book Value per Share1.1x
    ✓Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio1.1x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)0.30
    ✓Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value8.2%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=8.2%, ROC=50.3%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS27.2x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)7.4x
    ✓Dreman< 8x
    Valuation ReasonablenessP/E=27.2x, OE Yield=6.8%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=27.2x, FCF Yield=13.5%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=27.2x, P/B=1.1x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share7.4x
    ✓Ackman<= 25
    Price vs. Trailing Low142% of trailing low ($5.18)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+3.33%; #2266/6340 (top 35.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.9481; #1584/6449 (top 24.6%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS27.2x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share8.28x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+108.3%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.7136; #2177/5247 (top 41.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+13.28%; #484/4519 (top 10.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+19.74%; #1359/6202 (top 21.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Verdicts47% pass✓ 7✗ 8▾

    Split decision: 8 FAIL · 4 PASS · 2 BUY · 2 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (2/9)✓LynchBUY (6/7)✓GreenblattRank #320✓PiotroskiBUY (F-Score 8)✓DremanPASS (6/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✓AckmanPASS (5/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1037/2370 (Top 43.8%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency50% pass✓ 5✗ 6▾

    4 of 8 pass — Buffett, Munger, Akre +1 more object

    Current Ratio5.58
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-57.5%
    ✗Buffett> 10%
    ROIC - WACC-67.5%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)50.3%
    ✓Greenblatt> 25%
    Current Ratio Change YoY2.89 -> 3.04
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.54x -> 0.62x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities5.58
    ✓Dreman> 1.5
    Return on Invested Capital5.8%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-12.8%; FY2024: ROIC=-7.2%; FY2025: ROIC=6.0%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC6.0% (RR=100% x ROIC=6.0%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/3 years above 12% (latest 6.0%)
    ✗SleepROIC > 12% in a majority of years
  • Valuation models50% pass✓ 3✗ 3▾

    Models split on OPRX at $7.34 — fair values range $5.92–$35.63

    Graham fair value$6.45
    ✗Graham-13.8% margin vs $7.34
    Buffett fair value$5.92
    ✗Buffett-24.0% margin vs $7.34
    Lynch fair value$6.75
    ✗Lynch-8.7% margin vs $7.34
    Munger fair value$23.72
    ✓Munger+69.1% margin vs $7.34
    Pabrai fair value$8.20
    ✓Pabrai+10.5% margin vs $7.34
    Ackman fair value$35.63
    ✓Ackman+79.4% margin vs $7.34

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Business Services
Size: Micro Cap($138.3M)
Revenue: $109.4M+18.8% YoY
Net Income: $5.1M+125.5% YoY

Financial Snapshot

Operating Margin10.7%
Return on Equity4.0%
Debt / Equity0.20
Current Ratio3.04
EPS (Diluted)$0.27
Shares Retired−1.6% / −3.2% 2y

Shareholder Return

Fiscal 2025

Issued 1.6% of shares last year, 3.2% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-12
FY 2024
Sources
  • 10-K · 2026-03-12
FY 2023
Sources
  • 10-K · 2024-04-15
FY 2022
Sources
  • 10-K · 2023-03-10
FY 2021
Sources
  • 10-K · 2022-02-28
Market Cap$138.3Mcurrent------$201.9Mest.$102.5Mest.$256.6Mest.$306.7Mest.$747.9Mest.
Revenue$94.2M↓14%$21.6M↓17%$20.5M↓30%$19.8M↓10%$109.4M↑19%$92.1M↑29%$71.5M↑15%$62.5M↑2%$61.3M
Operating Income$11.5M↑71%$2.7M↑30%-$88.0K↓103%$396.0K↑119%$11.7M↑185%-$13.7M↑48%-$26.4M↓115%-$12.3M↓3504%$361.1K
Net Income$5.0M↑14656%$1.2M↑53%-$703.0K↓146%-$495.0K↑77%$5.1M↑126%-$20.1M↓14%-$17.6M↓54%-$11.4M↓3125%$378.1K
EPS (Diluted)--$0.06↑50%$-0.04↓150%$-0.03↑75%$0.27↑125%$-1.10↓7%$-1.03↓61%$-0.64↓3300%$0.02
Gross Margin————67.3%↑4%64.5%↑7%60.0%↓4%62.4%↑7%58.1%
Operating Margin12.3%↑99%12.4%↑57%-0.4%↓104%2.0%↑121%10.7%↑172%-14.9%↑60%-36.9%↓88%-19.7%↓3441%0.6%
ROE3.7%↑13376%———4.0%↑123%-17.2%↓24%-13.9%↓53%-9.1%↓3252%0.3%
Total Debt$12.7M↓55%$12.7M↓55%$19.0M↓33%$23.3M↓28%$25.7M↓22%$32.8M↓9%$36.2M----
Shareholders' Equity$133.9M↑10%$133.9M↑10%$131.1M↑10%$129.6M↑11%$128.3M↑10%$117.0M↓8%$126.6M$126.1M↓4%$131.4M
Current Ratio5.06↑66%5.06↑66%5.58↑117%5.37↑91%3.04↑5%2.89↓5%3.04↓74%11.74↓4%12.29
Debt / Equity0.10↓59%0.10↓59%0.15↓39%0.18↓36%0.20↓29%0.28↓2%0.29——
Operating Cash Flow$20.0M↑69%$4.7M↑48%$8.6M↑89%-$467.0K↓112%$18.7M↑283%$4.9M↑168%-$7.2M↓168%$10.7M↑1367%$726.0K
Free Cash Flow$19.9M↑69%$4.7M↑48%$8.6M↑88%-$488.0K↓113%$18.7M↑291%$4.8M↑165%-$7.3M↓169%$10.6M↑1590%$625.7K

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Business Services

OPRX vs Peers — Financial Grading

Revenue$109.4MBottom 25%
Net Income$5.1MMedian
ROE4.0%Bottom 25%
D/E0.20Top 25%
Op. Margin10.7%Top 25%
Curr. Ratio3.04Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
AUTOMATIC DATA PROCESSING INCADP$122.3B$309.93$21.9B$4.4B73.2%0.8224.2%1.054/95/93/70/3F-Score 65/11
ELECTRONIC ARTS INC.EA$52.9B$209.70$7.5B$887.0M13.1%0.2215.4%1.051/94/94/70/3F-Score 66/11
Rubrik, Inc.RBRK$22.6B$109.88$1.3B$348.8M67.1%—-26.2%1.691/90/92/70/3F-Score 62/11
AECOMACM$9.1B$70.50$16.1B$561.8M22.5%1.096.4%1.141/93/93/71/3F-Score 82/11
COMMVAULT SYSTEMS INCCVLT$6.2B$152.07$1.2B$70.7M942.8%—6.3%1.951/92/94/70/3F-Score 66/11
WPP plcWPP$6.0B$27.79$18.2B$289.5M-8.5%1.942.8%0.891/92/91/70/3F-Score 32/11
VARONIS SYSTEMS INCVRNS$5.6B$48.94$623.5M$129.3M-21.6%0.76-23.5%1.971/90/91/70/3F-Score 51/11
ROBERT HALF INC.RHI$4.3B$42.00$5.4B$133.0M10.4%—1.4%1.532/95/91/70/3F-Score 52/11